Nanobiotix S.A. (NASDAQ:NBTX - Get Free Report) saw a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 62,300 shares, a growth of 1,197.9% from the April 30th total of 4,800 shares. Currently, 0.1% of the company's shares are sold short. Based on an average daily trading volume, of 10,900 shares, the days-to-cover ratio is currently 5.7 days.
Institutional Trading of Nanobiotix
Several hedge funds and other institutional investors have recently added to or reduced their stakes in NBTX. Geode Capital Management LLC acquired a new position in shares of Nanobiotix in the 4th quarter valued at about $29,000. Millennium Management LLC acquired a new position in shares of Nanobiotix in the 4th quarter valued at about $39,000. Jane Street Group LLC acquired a new position in shares of Nanobiotix in the 4th quarter valued at about $73,000. Finally, OLD Mission Capital LLC acquired a new position in shares of Nanobiotix in the 4th quarter valued at about $139,000. Hedge funds and other institutional investors own 38.81% of the company's stock.
Wall Street Analyst Weigh In
NBTX has been the subject of several recent analyst reports. UBS Group upgraded Nanobiotix to a "hold" rating in a report on Monday, February 17th. Guggenheim lowered their price target on Nanobiotix from $12.00 to $8.00 and set a "buy" rating for the company in a report on Friday, April 4th.
Read Our Latest Research Report on Nanobiotix
Nanobiotix Stock Down 0.6%
NBTX traded down $0.02 during midday trading on Friday, hitting $4.11. The company's stock had a trading volume of 6,644 shares, compared to its average volume of 15,560. The firm has a 50-day moving average price of $3.49 and a two-hundred day moving average price of $3.43. Nanobiotix has a 52-week low of $2.76 and a 52-week high of $7.29.
About Nanobiotix
(
Get Free Report)
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Featured Articles
Before you consider Nanobiotix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nanobiotix wasn't on the list.
While Nanobiotix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
